State-licensed research programs create opportunities for controlled studies that can generate clinically relevant data on dosing, safety, and efficacy. Missouri’s initiative could contribute to the evidence base that clinicians desperately need for informed prescribing decisions.
Missouri is developing a framework for state-licensed cannabis research, joining other states in establishing regulated research programs outside federal constraints. This approach allows researchers to study cannabis products that patients actually use, rather than being limited to NIDA-supplied material. Such programs typically focus on clinical outcomes, safety profiles, and optimal dosing protocols that translate directly to patient care.
“We need real-world data on the products patients are actually using, not just studies on government cannabis that bears little resemblance to dispensary offerings. State research programs like this could finally bridge the gap between what we prescribe and what we actually know works.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
